Valeant CEO Pearson to leave company
March 21, 2016Michael Pearson, Valeant
Valeant (NYSE:VRX) has announced that it has begun the search for a new CEO, confirming that Michael Pearson is to …
AstraZeneca buys rights to Orexo respiratory programme
March 21, 2016Sales and Marketing AstraZeneca, COPD, asthma, orexo
AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …
Novartis’s heart failure drug given final recommendation by NICE
March 21, 2016Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug
The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …
NICE approves Janssen’s Zytiga for prostate cancer before chemo
March 21, 2016Sales and Marketing Janssen, NICE, Zytiga, prostate cancer
The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …
TREND: Smallcap biotechs win in stock markets on positive drug trials
March 21, 2016Research and Development, Sales and Marketing
Troubled Canadian drug firm Valeant Pharma (NYSE: VRX) saw its share price halved in a single day after the company …
Pfizer India names S Sridhar MD
March 21, 2016Business Services, Sales and Marketing Executive appointment, Pfizer Inc, Pfizer India
Pfizer India (BOM: 500680) has named S Sridhar the company’s managing director for a five-year term, effective March 18. Sridhar …
Further positive trial results boost Amgen and UCB’s romosozumab
March 21, 2016Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval
Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …
Celgene’s ozanimod meets endpoints in Phase II ulcerative colitis trials
March 21, 2016Research and Development, Sales and Marketing Celgene
Celgene International SÃ rl, a Celgene subsidiary, has announced additional data of exploratory endpoints from a Phase II trial of ozanimod …
US FDA rejects application for Eagle Pharma’s blood thinner; shares plunge
March 21, 2016Research and Development, Sales and Marketing Eagle Pharmaceuticals, Kangio, US FDA, blood thinner
Shares in Eagle Pharmaceuticals (Nasdaq: EGRX) closed down almost 19% Friday after the US Food and Drug Administration rejected the …
Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials
March 21, 2016Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis
Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …
J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease
March 18, 2016Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease
Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
Wales approve pancreatic cancer drug for use despite NICE rejection in England
March 18, 2016Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval
Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
Study data supports switch to Celltrion’s Remicade biosimilar
March 18, 2016Research and Development
Celltrion and distribution partner Mundipharma have presented study data supporting switching irritable bowel disease (IBD) patients from Remicade to biosimilar …
Indian govt set to ban 1,200 fixed-dose combination drugs, reports
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abbott Laboratories, Pfizer, cough drug, pharma
Indian regulators are set to ban an additional 1,200 fixed-dose combinations, sent for probe by Drug Controller General of India …
OncoMed initiates Phase Ib immuno-oncology combination clinical trial
March 18, 2016Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
Allergan files ANDA for generic version of Celgene’s breast cancer treatment
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic
Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …
Gilead cancer boss departs after safety concerns halt Zydelig trials
March 18, 2016Medical Communications, Research and Development Gilead Sciences, zydelig
In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …
Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma
March 18, 2016Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma
Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy …
FDA approves Breckenridge’s generic of Pfizer’s anti-epilepsy drug
March 18, 2016Research and Development, Sales and Marketing FDA, Neurontin, Pfizer, anti-epilepsy, approval, breckenridge, gabapentin, tris pharma
Breckenridge Pharmaceutical Inc. has announced that their generic of Pfizer’s anti-epilepsy drug Neurontin (gabapentin) has been approved by the US …
Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi
March 17, 2016Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis
US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
